Safety and tolerability of zoster vaccine in adults ≥60 years old

Background paper to the decision not to recommend a standard vaccination with the live attenuated herpes zoster vaccine for the elderly in Germany

“…A total of 5 RCTs were included to assess the safety of the live HZ vaccine [36,37,[42][43][44][45]. They vary widely with regard to their consideration of the relevant endpoints and participant numbers.…”

Preventing and managing herpes zoster: key actions to foster healthy aging

“…-In two population-based studies, the vaccine was associated with a 55 and 51 % reduction in incidence of HZ among the immunocompetent population, respectively, aged C60 and C65 [63,64]. -The first results showed that the vaccine's effectiveness against PHN reached 59 % in the general population aged C65 (including both immunocompetent and immunosuppressed individuals) [64].…”

“…-The first results showed that the vaccine's effectiveness against PHN reached 59 % in the general population aged C65 (including both immunocompetent and immunosuppressed individuals) [64]. -Another retrospective study on subjects enrolled in Medicare, aged [60 years (average age 74 ?…”

Zoster vaccine (Zostavax®): a guide to its use in preventing herpes zoster and postherpetic neuralgia

“…[7,9,15] In the 42-day post-immunization period in the total Shingles Prevention Study population, the incidence of serious adverse events was 1.4% in both zoster vaccine and placebo recipients. [7] Likewise, in a randomized, double-blind safety study in 11 980 vaccinated adults aged ‡60 years, [15] the estimated risk of serious adverse events was not significantly …”